Condition
Pancreatic Cancer, Resected
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07072897Not ApplicableCompletedPrimary
A Study Comparing Restrictive and Liberal Fluid Therapy During Pancreatecoduodenectomy Surgery
NCT06960122Not ApplicableNot Yet RecruitingPrimary
Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
NCT02261714Phase 1CompletedPrimary
Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
Showing all 3 trials